NCT03279978View on ClinicalTrials.gov

This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

August 24, 2018

Study Completion Date

August 30, 2018

Conditions
HealthyPsoriasis
Interventions
DRUG

BI 730357

BI 730357 film-coated tablet

DRUG

Placebo

Placebo

DRUG

Midazolam

Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed

Trial Locations (1)

20251

CTC North GmbH & Co. KG, Hamburg, Hamburg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03279978 - This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357 | Biotech Hunter | Biotech Hunter